



## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

Dear All,

We would like to bring to your attention a few funding opportunities that might be of interest to you. Please find below details:

### MENTAL HEALTH AWARD: USING PHYSICAL ACTIVITY AND CIRCADIAN-BASED INTERVENTIONS TO REDUCE ANXIETY AND DEPRESSION IN YOUNG PEOPLE

**Funding Body:** Wellcome Trust

**Objectives:** This award will fund mechanistically informed trials of interventions for anxiety and depression in young people aged 10-18 years. Successful teams will build on existing mechanistic evidence to develop more precise and effective early interventions that have the potential to scale.

**Eligibility:** Researchers from any relevant discipline. The administering organisation can be based anywhere in the world apart from mainland China.

**Budget:** £1-4 million per grant

**Deadline:** June 14, 2026 (Application)

**Link:** [here](#)

### UNDERSTANDING THE IMPACT OF AGING IN MULTIPLE SCLEROSIS

**Funding Body:** National Multiple Sclerosis Society

**Objectives:** This request for applications (RFA) aims to support early, developmental, and feasibility studies that will address critical gaps in understanding how chronological and biological aging affect MS.

**Eligibility:** Applicants must hold an MD, PhD, or the equivalent. This RFA is open to investigators at not-for-profit research institutions. Collaborations with commercial organizations are allowed.

**Budget:** Maximum of \$200,000 direct costs for 2 years

**Deadline:** June 17, 2026 (LOI); September 9, 2026 (full proposal)

**Link:** [here](#)

### QUARTERLY RESEARCH GRANT FUNDING PROGRAMME

**Funding Body:** Cure Parkinson's

**Objectives:** This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson's. For preclinical research, priority is given to projects leading to clinical trials in people with Parkinson's within 5 years. For clinical research, the funder supports clinical trials and sub-studies of trials in people with Parkinson's.

**Eligibility:** Applications are accepted internationally from academics and commercial entities.

**Budget:** For preclinical research, grants up to £250,000 (GBP) are funded.

**Deadline:** June 22 and October 12, 2026

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### CLINICAL CANCER RESEARCH GRANTS

**Funding Body:** Rising Tide Foundation (RTF)

**Objectives:** The aim of these grants is to collaborate on innovative, patient-centered clinical trials. The mission is to improve cancer patients' treatment options and quality of life by funding studies focused on detection, treatment, and implementation. The Foundation supports phase I to phase III interventional clinical trials but do not fund basic research, phase IV trials, or observational studies.

**Eligibility:** Funding is available to institutions worldwide where effective grant oversight is feasible.

**Budget:** The Foundation does not cover the full clinical trial cost. It funds USD 100,000 per each year of the trial duration

**Deadline:** June 22 and November 23, 2026 (LOI)

**Link:** [here](#)

### CLINICAL TRIALS TO VALIDATE AI-DRIVEN DRUG REPURPOSING

**Funding Body:** Cures Within Reach (CWR)

**Objectives:** This RFP is seeking investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease from anywhere in the world, where the therapies supported by AI models are already approved. Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial. The results of the overall AI workflow should clearly support the repurposing hypothesis and/or any existing preclinical data and be explainable in a clinical setting.

**Eligibility:** Kindly refer to the link below for detailed eligibility criteria

**Budget:** 100,000

**Deadline:** June 26, 2026 (LOI)

**Link:** [here](#)

### MANPEI SUZUKI INTERNATIONAL PRIZE FOR DIABETES RESEARCH

**Funding Body:** Suzuki Diabetes Foundation

**Objectives:** The Manpei Suzuki International Prize is for original and excellent achievements in diabetes research. By providing this opportunity to researchers of the world, we hope to advance diabetes research that will contribute to the health and welfare of all people.

**Eligibility:** Kindly refer to the link below for further information regarding the scope of the Nomination Application, as well as the Nominator and Nominee.

**Budget:** \$200,000 prize

**Deadline:** July 1, 2026

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### FIBROLAMELLAR RESEARCH FUNDING

**Funding Body:** Fibrolamellar Cancer Foundation (FCF)

**Objectives:** FCF aims to drive and support high-impact research that is critical for the discovery of better treatments for FLC.

-Applicants must be employed by an institution engaged in health-related research.

-The research must focus on Fibrolamellar Carcinoma (FLC) [also known as Fibrolamellar Hepatocellular Carcinoma (FL-HCC)].

**Eligibility:**

-Collaboration and open sourcing are a requirement for funding by FCF and will be specified in any grant agreement.

**Budget:**

Depending on application category; there is no fixed “magic number” for the scope and funding of a worthy project. Rather, researchers are asked to submit a proposal with appropriate budget as needed to support clear specific aims and/or milestones.

**Deadline:**

July 1 and November 1, 2026 (Application)

**Link:**

[here](#)

### KELLOGG FAMILY EARLY-CAREER PATIENT-ORIENTED DIABETES RESEARCH AWARD

**Funding Body:** Breakthrough T1D

**Objectives:**

This award is designed to provide crucial support to investigators who plan to pursue a career in diabetes-related clinical investigation. Awards are made in the later stages of training and include the ability for recipients to transition to independent faculty or research appointments.

**Eligibility:**

**Institutional Eligibility**

Domestic & foreign non-profit organizations; public & private universities, colleges, hospitals, laboratories; units of state & local governments; eligible agencies of the federal government.

**Applicant Eligibility**

In most cases, applicant will have an MD, MD-PhD, DO, or PsyD, hold an appointment or joint appointment in a subspecialty of clinical medicine, and conduct human clinical research.

**Budget:**

200,000 USD maximum/year for up to 5 years, including up to 10% for indirect costs and generally not renewable after 5 years.

**Deadline:**

July 2, 2026 (Full proposal)

**Link:**

[here](#)

### CAREER DEVELOPMENT AWARDS

**Funding Body:** Breakthrough T1D

**Objectives:**

These awards are designed to attract qualified and promising scientists early in their faculty careers and to give them the opportunity to establish themselves in areas that reflect the Breakthrough T1D research emphasis areas.

**Eligibility:**

Similar to the above.

**Budget:**

200,000 USD maximum/year for up to 5 years, including up to 10% for indirect costs and generally not renewable after 5 years.

**Deadline:**

July 2, 2026 (Full proposal)

**Link:**

[here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### E.W. "AL" THRASHER AWARDS

**Funding Body:** Thrasher Research Fund

**Objectives:** E.W. "Al" Thrasher Awards focus on projects that are changing pediatric clinical care. The award is open to applications focusing on any disease or topic within the umbrella of pediatrics, both in and outside the United States. Ideal applications address significant health problems, offering the potential for practical solutions to these problems. Typically, the primary outcome is a health outcome in children. Solutions should be innovative and have the potential for broad applicability with low barriers to implementation. Projects with a shorter distance to clinical applicability are given priority. Hypothesis-driven research is critical, exploratory, or hypothesis-generating research will not be competitive. For projects focused on improving disease diagnosis, well researched and effective treatment options available to patients upon diagnosis should be included.

**Eligibility:** There are no citizenship or residency requirements. The Fund is open to applications from institutions both inside and outside the United States.

**Budget:** The grant amount is based on the actual budgetary needs of the project. The duration of the project can be up to three years. Indirect costs are no more than 7% of direct costs. In 2020-2025 the median grant was \$420,000. Grants are generally not given over \$600,000

**Deadline:** July 14, 2026 (Concept note)

**Link:** [here](#)

### SHAFFER GRANTS FOR INNOVATIVE GLAUCOMA RESEARCH

**Funding Body:** Glaucoma Research Foundation

**Objectives:** The Foundation aims to fund projects that support new high-impact clinical, epidemiological, and laboratory research based on its strategic research goals. There are now two focus areas for Shaffer Grants: one for the physiology of glaucoma and a second to advance the genetics of glaucoma.

**Eligibility:** AUB faculty members who comply with the Call for Applications' terms and specifications are eligible to apply. Researchers interested in applying for a Shaffer Grant must first submit a preliminary proposal for consideration. Grant applicants must possess a graduate degree, not have received a Shaffer Grant within the prior three years, and agree to acknowledge the Glaucoma Research Foundation in papers and abstracts resulting from Glaucoma Research Foundation-funded research.

**Budget:** \$55,000. Overhead not allowed.

**Deadline:** July 15, 2026 (Preliminary proposals)

**Link:** [here](#)

### YOUNG INVESTIGATOR AWARD IN PEDIATRIC BRAIN TUMORS

**Funding Body:** Conquer Cancer, the ASCO Foundation

**Objectives:** The opportunity aims to support early-career investigators conducting research in pediatric brain tumors.

**Eligibility:** Applicants are generally expected to: be early-career researchers, hold an MD, PhD, or equivalent advanced degree, be affiliated with an eligible academic, research, or clinical institution, and work under mentorship/support if still in training or junior stages. For further details, please refer to the link below.

**Budget:** \$50,000 for one year

**Deadline:** July 15, 2026 (Application)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### WELLCOME EARLY-CAREER AWARDS

**Funding Body:** Wellcome Trust

**Objectives:** This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing.

**Eligibility:** Applications are accepted from early-career researchers in any relevant discipline.

**Budget:** The salary of the early-career researcher and up to £400,000 for research expenses.

**Deadline:** July 21, 2026

**Link:** [here](#)

### WELLCOME CAREER DEVELOPMENT AWARDS

**Funding Body:** Wellcome Trust

**Objectives:** This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders.

**Eligibility:** Mid-career researchers from low- or middle-income countries who are ready to lead a substantial and innovative research program.

**Budget:** The annual expenditure for a Career Development Award is usually below £250,000 excluding the applicant's salary. Applications above this value will be subject to additional scrutiny.

**Deadline:** July 28, 2026

**Link:** [here](#)

### RESEARCH GRANTS

**Funding Body:** National MPS Society

**Objectives:** This supports innovative research on mucopolysaccharidosis (MPS) and mucopolipidosis (ML), spanning basic, translational, and clinical science.

**Eligibility:** Any domestic US or foreign, public or private, non-profit or for-profit research organization is eligible to apply for and receive a Society Research Grant.

**Research Tier I, II, or III Grants:**

-Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as a Principal Investigator (PI) is invited to apply.

-A PI must be institutionally eligible to apply for, be awarded, and administer an extramural research grant.

**Research/Clinical Scientist Fellow-Initiated Research Grants:**

-Eligible applicants include PhD candidates and medical professional students, and post-doctoral fellows.

-Fellow applicants must have a principal mentor who satisfies the institutional requirements of a PI as defined above under the Research Tier I and II Grants heading.

**Budget:** **Tier I Research Grant:** Up to a total of \$100,000 US, disbursed over one to two years at the discretion of the PI; **Tier II Research Grant:** Principle Investigator (PI) Initiated: Up to a total of \$50,000 US, disbursed over one to two years at the discretion of the PI; **Research Tier III Grant:** Up to a total of \$25,000 US, disbursed over one year; **Fellow-initiated Research Grant:** Funding: \$50,000 for 1 year.

**Deadline:** August 7, 2026 (LOI)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### OPEN CALL FOR RESEARCH PROPOSALS

**Funding Body:** Angelman Syndrome Foundation, Inc. (ASF)

**Objectives:** The Foundation is committed to funding groundbreaking scientific research that brings us closer to effective treatments and improved care for individuals with Angelman syndrome (AS). The Full Research Roadmap is available [here](#)

**Eligibility:** Scientists and clinicians worldwide to submit innovative studies that align with our 2025 ASF Research Roadmap and priorities.

**Budget:** Up to \$100,000 per year

**Deadline:** August 15, 2026

**Link:** [here](#)

### GENERAL RESEARCH GRANT

**Funding Body:** Friedreich's Ataxia Research Alliance (FARA)

**Objectives:** The General Research Grant is open to qualified investigators proposing projects that align with [FARA Research Priorities](#).

**Eligibility:** Public and private nonprofit universities, colleges, hospitals, laboratories, government agencies, biotechnology/pharmaceutical companies, and other for-profit entities; irrespective of the country of origin as permitted by law. FARA particularly encourages junior investigators to submit LOIs.

**Budget:** Up to \$125,000 per year for 1 or 2 years

**Deadline:** August 15, 2026 (LOI); October 15, 2026 (Application)

**Link:** [here](#)

### RESEARCH GRANTS

**Funding Body:** LEO Foundation

**Objectives:** The aim is to improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms. Applications for projects that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved, are also welcome.

**Eligibility:** Any researcher who has obtained at least a PhD degree or equivalent academic qualifications may apply. They must be affiliated with a university, hospital, or other non-profit organization based anywhere in the world.

**Budget:** DKK 2-4 million for or a period of 1-3 years.

**Deadline:** August 25, 2026 (Application; Call opens on June 29)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### RESEARCH GRANTS

**Funding Body:** Merck Group

**Objectives:** For the 2026 funding cycle, Merck is inviting proposals in the following priority focus areas:

- In-vitro models and assays to identify novel therapies for neuroinflammatory diseases - one grant of up to 250,000 EUR per year for up to 2 years.
- Artificial intelligence in cell culture media and process development - one grant of up to 150,000 EUR per year for up to 3 years.
- Innovative approaches to economical remediation of contaminated high volume materials - one grant of up to 150,000 EUR per year for up to 2 years.
- Condensate-based high-sensitivity cell-free screening assays for the modulation of protein-protein interactions - one grant of up to 100,000 EUR per year for up to 3 years.
- Advancing molecule synthesis and discovery - up to 3 grants each comprising a 1-year full Synthia® Retrosynthesis Software license, training, and extensive interaction with our scientists.

**Eligibility:** Scientists at all career stages, Researchers affiliated with universities, research-based institutions, or companies and Applicants from both academic and industrial research environments. There are no restrictions based on seniority, discipline background, or geographic location, provided institutional affiliation requirements are met.

**Budget:** Up to €500,000 per year, for a maximum duration of three years, depending on the focus area.

**Deadline:** August 31, 2026

**Link:** [here](#)

### INVESTIGATOR SPONSORED RESEARCH

**Funding Body:** Pfizer

**Objectives:** Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about their therapies.

**Eligibility:** This global program is open to all researchers who are interested in conducting their own research.

**Budget:** Unspecified

**Deadline:** September 9, 2026

**Link:** [here](#)

### DRUG DEVELOPMENT RFP

**Funding Body:** Alzheimer's Drug Discovery Foundation

**Objectives:** This RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias.

**Eligibility:** Researchers worldwide at academic medical centers/universities. Industry partnerships are encouraged.

**Budget:** Up to \$5,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

**Deadline:** September 14, 2026 (LOI)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### PREVENTION RFP

**Funding Body:** Alzheimer's Drug Discovery Foundation

**Objectives:** This initiative supports research on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer's and dementia risk. Focus areas include targeted interventions for modifiable and genetic risk factors, synergistic drug combinations, and evaluating clinically equivalent drugs for superior dementia prevention outcomes.

**Eligibility:** Researchers and clinicians worldwide at academic medical centers and universities or nonprofits and biotechnology companies. Existing companies and new startups are both eligible.

**Budget:** Up to \$5,000,000 for clinical trials based on stage and scope of research.

**Deadline:** September 14, 2026 (LOI)

**Link:** [here](#)

### NEUROIMAGING AND CSF BIOMARKER PROGRAM

**Funding Body:** Alzheimer's Drug Discovery Foundation

**Objectives:** The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

**Eligibility:** Researchers worldwide at academic medical centers/universities. Industry partnerships are encouraged.

**Budget:** Up to \$600,000 based on stage and scope of research. Only direct costs are allowed.

**Deadline:** September 14, 2026 (LOI)

**Link:** [here](#)

### CLINICAL RESEARCH PROPOSALS

**Funding Body:** ResMed Foundation

**Objectives:** The aim of these proposals is to support innovative research on sleep disordered breathing (SDB) and respiratory disorders, emphasizing diagnosis, treatment, and management. Focus areas include comorbidities like cardiovascular diseases, metabolic syndrome, insomnia, asthma, COPD, and applications of AI/ML, remote monitoring, health economics, and clinical outcomes translation.

**Eligibility:** Donor recipients must be a qualified tax-exempt organization under section 501 (c) 3 of the US Internal Revenue Service or have the equivalent designation by the federal governing agency in another country. Please refer to the link below for further details.

**Budget:** Currently the Foundation plans to disburse a total of up to \$1,350,000 annually.

**Deadline:** September 15 and December 15, 2026 (Application)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### WELLCOME DISCOVERY AWARDS

**Funding Body:** Wellcome Trust

**Objectives:** This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing.

**Eligibility:** Low- or middle-income countries (apart from India and mainland China) including Lebanon.

**Budget:** The average size of a Discovery Award is £3.5 million. Applications above £5 million will be subject to additional scrutiny. Awards can be up to 8 years, but may be less for some disciplines, and may be longer if held on a part-time basis. The average duration of a Discovery Award is 7 years, although awards from 3 to 8 years have been supported.

**Deadline:** September 22, 2026

**Link:** [here](#)

### RESEARCH GRANTS

**Funding Body:** Morton Cure Paralysis Fund (MCPF)

**Objectives:** MCPF funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization. Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a 'change of direction.'

**Eligibility:** Qualified scientists at capable institutions will be considered for grant applications. Either senior scientists or postdoctoral fellows may serve as principal investigators.

**Budget:** from \$5,000 to \$75,000

**Deadline:** September 30, 2026

**Link:** [here](#)

### ARVO FOUNDATION RESEARCH CATALYST AWARD

**Funding Body:** ARVO Foundation for Eye Research (AFER)

**Objectives:** The ARVO Foundation Research Catalyst Award is intended for investigators beginning their careers or returning to the workforce after an extended leave.

**Eligibility:** Early-career researchers in vision science.

**Budget:** \$70,000. Research projects must be completed within two years.

**Deadline:** October 1, 2026 (Application)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### PROGRAM SUPPORT: ADVANCING GLOBAL CARDIAC AND MATERNAL HEALTH

**Funding Body:** Laerdal Foundation

**Objectives:** The aim is to support research projects advancing resuscitation, trauma, and maternal/ newborn care.

**Eligibility:** For detailed eligibility notes, please refer to the link below.

**Budget:** Program support may be applied for up to USD 150,000 for each of three consecutive years for programs that support the Foundation's strategy. Institutional overhead costs can be covered up to 10%.

**Deadline:** October 1, 2026 (Concept proposal)

**Link:** [here](#)

### PROJECT SUPPORT

**Funding Body:** Laerdal Foundation

**Objectives:** This supports applications that relate to factors 2 and 3 of the Utstein Formula for Survival .

**Eligibility:** For detailed eligibility notes, please refer to the link below.

**Budget:** \$50,000

**Deadline:** October 1, 2026 (Concept proposal)

**Link:** [here](#)

### NCSBN GRANT PROGRAM

**Funding Body:** National Council of State Boards of Nursing (NCSBN)

**Objectives:** The NCSBN Grant Program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide. Research Priorities are available [here](#)

**Eligibility:** For detailed eligibility notes, please refer to the link below.

**Budget:** Up to \$300,000

**Deadline:** October 2, 2026 (Proposal)

**Link:** [here](#)

### RESEARCH GRANTS

**Funding Body:** Cure JM Foundation

**Objectives:** The Foundation offers grant funding for clinicians and researchers who are working to improve juvenile myositis care and research.

**Eligibility:** Applicants must hold a Ph. D. or M.D. degree or equivalent and work in an accredited medical school, university, hospital or research institute which must agree to supply the clinical and/or laboratory facilities. The foundation strongly encourages collaborations from two or more institutions that bring together a spectrum of expertise. Grant applications are called for across programs relating to all aspects of; basic research, clinical trials, translational studies, diagnosis and clinical care of juvenile myositis.

**Budget:** Up to \$75K/year for up to 2 years with preference for individuals who have at least 25% protected research time from their institution (the award does not provide indirect costs).

**Deadline:** October 31, 2026 (Application)

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### SCIENCE AND TECHNOLOGY AWARDS

**Funding Body:** CooperVision

**Objectives:** This award supports pioneering research in myopia control, focusing on novel technologies, biomarkers, mechanisms of onset and progression, structural changes, and therapy selection. It encourages visionary projects that challenge conventional treatment paradigms in ophthalmology and vision disorders.

**Eligibility:** Any researcher with Principal Investigator status holding a MD, OD, or PhD is eligible to apply.

**Budget:** \$100,000

**Deadline:** Rolling

**Link:** [here](#)

### INNOVATION AWARDS

**Funding Body:** PTEN Research

**Objectives:** These support clinical, pre-clinical, and basic research projects which support new and better treatments and improved outcomes for people with PTEN hamartoma tumour syndrome (PHTS) that align with the foundation's strategic research focus. **Clinically focused projects or preclinical projects with translational potential** are prioritized. The foundation is particularly interested in multicentre and consortium funding applications that combine analysis of banked biosamples and/or clinical data. Exceptional basic research projects including those with a focus on target identification will also be considered.

**Eligibility:** Eligibility to apply for funding is not restricted to any specific geography. In general, PTEN Research provides grants to Principal Investigators who have qualified with an MD or PhD and have an established research programme in a recognised academic or clinical research institution.

**Budget:**

- PTEN Research will provide funding for approved preclinical/translational medicine research projects up to a maximum of £270,000 GBP (or equivalent currency).
- This cap applies to new Innovation Awards Project Proposals and encompasses all project costs, including but not limited to materials, consumables, equipment, staff costs, and research-related travel.
- PTEN Research may, at its sole discretion, consider a waiver of the funding cap for preclinical/translational medicine projects that demonstrate exceptional scientific merit and promise for advancing the field, and have high strategic importance. If applicants wish to submit an application that exceeds the maximum funding amount, it is strongly recommended to contact the Foundation to discuss further before making a submission.
- For avoidance of doubt, the funding cap does not apply to clinical research projects, including but not limited to interventional clinical studies, patient registries and natural history studies, clinical endpoint development, and epidemiological studies.

**Deadline:** Project Proposal applications will be accepted on an ongoing basis. Projects that represent exceptional research opportunities and align with the Foundation's research strategy will be invited to submit a Full Application.

**Link:** [here](#)





## ANNOUNCEMENT FOR FUNDING OPPORTUNITIES

May 12, 2026

### PITT HOPKINS SYNDROME GRANTS

**Funding Body:** Pitt Hopkins Research Foundation

**Objectives:**

The mission of the Pitt Hopkins Research Foundation (PHRF) is to support research dedicated to finding a treatment, and an eventual cure for Pitt Hopkins Syndrome and other similar disorders. The PHRF is also dedicated to supporting the Pitt Hopkins community with resource recommendations, parental support and the latest medical information.

**Eligibility:**

Institutions receiving grants must be recognized as nonprofit. Individuals should have training and experience at least equal to the Ph.D. or M.D. level. Awardees are required to pursue their research training on a full-time basis, normally defined as 40 hours per week, or as specified by the sponsoring institution in accordance with its own policies.

**Budget:** \$75,000

**Deadline:** No deadline

**Link:** [here](#)

### NEUROFIBROMATOSIS THERAPEUTIC ACCELERATION PROGRAM (NTAP)

**Funding Body:** Johns Hopkins University School of Medicine

**Objectives:** The Program supports research projects designed to accelerate development of effective treatments for NF1 associated peripheral nerve sheath tumors through the Open Proposal Program.

**Eligibility:** Any PI (regardless of the location/primary research focus) who has a proposal related to NF1 associated peripheral nerve sheath tumors (cutaneous neurofibroma, plexiform neurofibroma and atypical neurofibroma)

**Budget:** No limit for direct and total costs but the direct costs should be appropriate and well justified (indirect costs: 10%)

**Deadline:** There is no Deadline for Submission. Applications are reviewed on a rolling basis throughout the year

**Link:** [here](#)





AMERICAN  
UNIVERSITY OF BEIRUT  
FACULTY OF MEDICINE

CLINICAL  
RESEARCH  
INSTITUTE



If you are interested in any of the funding opportunities listed above, please contact **Ms. Lyn Sinno** at the Clinical Research Institute via email at [ls109@aub.edu.lb](mailto:ls109@aub.edu.lb) or through the following:  
Tel: 961-1-350000; Ext. 5776 and coordinate with the Pre-Award Unit at the Office of Research (**Ms. Leen Haydar**: [lh44@aub.edu.lb](mailto:lh44@aub.edu.lb)) for internal review, submission procedures, and guidance on required documents.